Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane (HISTORIX)
Status
Conditions
Treatments
Details and patient eligibility
About
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.
Full description
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in patients with severe acute kidney injury or sepsis, compared with standard membranes. Based on this benefit, the use of oXiris may confer better outcomes than other membranes.
The patient outcomes include cardiovascular, respiratory, renal, and overall survivals, but this information of oXiris are insufficient. Although cytokine and endotoxin removal rates are great in oXiris, the beneficial effects on the hard outcomes are needed to use oXiris in real clinical practice.
The inflammatory and cardiovascular systems have intensive crosstalk, and thus if there are remission in inflammatory process, the patients can have hemodynamic stability. Regarding this, the investigators would like to compare the hemodynamic stability between oXiris and other standard membrane such as polysulfone, using our new real-time monitoring registry.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Aged ≥ 18 years
- Sepsis related acute kidney injury requiring continuous renal replacement therapy
Exclusion criteria
• No monitoring of blood pressure and ECG
Trial design
98 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Seung Seok Han, M.D.; Donghwan Yun, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal